On July 25th, the U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear oral arguments regarding the consolidation of diabetic drug lawsuits involving two popular medications: Byetta & Januvia.
Byetta and Januvia, both used to treat Type 2 Diabetes have recently been associated with an increased risk of pancreatic cancer. The diabetes and pancreatic cancer study linking Byetta and Januvia with cancer of the pancreas was published earlier this year. However, there are already 53 pending Januvia and Byetta lawsuits brought on by plaintiffs who allege Januvia, Byetta, and other incretin mimetic diabetes medications caused them to develop Pancreatic Cancer.
The motion to centralize the diabetic drug litigation was filed in April. If consolidated, the Multi-District Litigation (MDL) will include not only Byetta and Januvia lawsuits, but Janumet and Victoza lawsuits as well.